In turn, the jury has put Amgen on the hook to pay Regeneron $135.6 million in compensatory damages and another $271.2 million in punitive damages, according to a verdict form filed Thursday.

Amgen today announced new interim results from the global Phase 3 DeLLphi-304 trial showing IMDELLTRA® (tarlatamab-dlle) reduced the risk of death by 40% and significantly extended median overall ...

including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent ...

Amgen has won FDA approval for a stronger label for its oral plaque psoriasis therapy Otezla, as it prepares for competition from Bristol-Myers Squibb's much-touted rival deucravacitinib ...

Thousand Oaks, CA-based Amgen is one of the biggest biotech companies ... Other products are Repatha, Blincyto, Vectibix, Nplate, Kyprolis, Evenity, Otezla, Aimovig, Lumakras/Lumykras, Tezspire ...

We recently published a list of The Best and Worst Dow Stocks. In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against other Dow stocks. The Dow Jones ...

The pharmaceutical company claimed Amgen bundled anti-inflammatory drugs Enbrel and Otezla to convince pharmacy benefit managers to select Repatha as the exclusive PCSK9 category product over ...

Amgen has gotten caught up in the broader market decline, but its business is unscathed. Its obesity drug sales are about to boom, making the stock look like a buy.

The pharmaceutical company claimed Amgen bundled anti-inflammatory drugs Enbrel and Otezla to convince pharmacy ... on this site does not imply any form of partnership, agency, or endorsement.

Teprotumumab approved as first targeted treatment for thyroid eye disease The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Amgen’s Tepezza ...